Matches in SemOpenAlex for { <https://semopenalex.org/work/W2273948891> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W2273948891 endingPage "3119" @default.
- W2273948891 startingPage "3119" @default.
- W2273948891 abstract "3119 Background: Clinical studies of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) as monotherapy in breast cancer patients have shown some evidence of activity. Significant relief of bone pain in patients with bone metastases was observed in a clinical trial of the EGFR-TKI gefitinib (IRESSA) in patients with metastatic breast cancer. Methods: The expression and functional role of EGFR, as well as the effects of gefitinib (4 μM) on the ability to produce osteoclastogenic factors, were investigated by reverse-transcriptase PCR, Real-Time PCR, Western blot analysis, immunoprecipitation, and/or ELISAs in 2 human bone marrow-derived continuous mesenchymal-stem-cell-like cell lines, HDS-1 and HDS-2. Results: Immunohistochemical analysis of bone marrow biopsies showed that human primary bone marrow stromal cells (BMSC) express immunoreactive EGFR. Expression of EGFR mRNA and protein was also demonstrated in both HDS cell lines. The levels of activated EGFR were significantly increased in HDS cells following treatment with EGF; this activation was blocked by gefitinib. Gefitinib reduced basal levels of activated EGFR and Akt in HDS cells. Treatment of HDS cells with gefitinib significantly reduced levels of secreted macrophage colony-stimulating factor (p<0.001, Student t-test) and cell-associated receptor activator of NF-kB ligand (RANKL) [p<0.05, Student t-test]. In contrast, no significant effects of gefitinib on the secretion of osteoprotegerin, a RANKL decoy receptor that inhibits osteoclast differentiation, were observed in HDS cells. Finally, the ability of conditioned medium from gefitinib-treated HDS cells to sustain the differentiation of pre-osteoclasts was reduced by ∼45% compared with untreated HDS cells (p<0.001, Student t-test). Conclusions: These data demonstrate that EGFR regulates the ability of BMSC to induce osteoclast differentiation and strongly support clinical trials of gefitinib in patients with breast cancer and bone metastases. IRESSA is a trademark of the AstraZeneca group of companies Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration AstraZeneca" @default.
- W2273948891 created "2016-06-24" @default.
- W2273948891 creator A5003014678 @default.
- W2273948891 creator A5006278471 @default.
- W2273948891 creator A5030954458 @default.
- W2273948891 creator A5035514953 @default.
- W2273948891 creator A5038345474 @default.
- W2273948891 creator A5054637398 @default.
- W2273948891 creator A5069468224 @default.
- W2273948891 creator A5089331461 @default.
- W2273948891 date "2005-06-01" @default.
- W2273948891 modified "2023-10-16" @default.
- W2273948891 title "Gefitinib reduces the production of osteoclast differentiation factors in human bone marrow stromal cells: Implications for treatment of bone metastasis" @default.
- W2273948891 doi "https://doi.org/10.1200/jco.2005.23.16_suppl.3119" @default.
- W2273948891 hasPublicationYear "2005" @default.
- W2273948891 type Work @default.
- W2273948891 sameAs 2273948891 @default.
- W2273948891 citedByCount "0" @default.
- W2273948891 crossrefType "journal-article" @default.
- W2273948891 hasAuthorship W2273948891A5003014678 @default.
- W2273948891 hasAuthorship W2273948891A5006278471 @default.
- W2273948891 hasAuthorship W2273948891A5030954458 @default.
- W2273948891 hasAuthorship W2273948891A5035514953 @default.
- W2273948891 hasAuthorship W2273948891A5038345474 @default.
- W2273948891 hasAuthorship W2273948891A5054637398 @default.
- W2273948891 hasAuthorship W2273948891A5069468224 @default.
- W2273948891 hasAuthorship W2273948891A5089331461 @default.
- W2273948891 hasConcept C121608353 @default.
- W2273948891 hasConcept C126322002 @default.
- W2273948891 hasConcept C16930146 @default.
- W2273948891 hasConcept C170493617 @default.
- W2273948891 hasConcept C2776033226 @default.
- W2273948891 hasConcept C2779428903 @default.
- W2273948891 hasConcept C2779438470 @default.
- W2273948891 hasConcept C2780007613 @default.
- W2273948891 hasConcept C2780426850 @default.
- W2273948891 hasConcept C2780580887 @default.
- W2273948891 hasConcept C502942594 @default.
- W2273948891 hasConcept C71924100 @default.
- W2273948891 hasConcept C88045685 @default.
- W2273948891 hasConceptScore W2273948891C121608353 @default.
- W2273948891 hasConceptScore W2273948891C126322002 @default.
- W2273948891 hasConceptScore W2273948891C16930146 @default.
- W2273948891 hasConceptScore W2273948891C170493617 @default.
- W2273948891 hasConceptScore W2273948891C2776033226 @default.
- W2273948891 hasConceptScore W2273948891C2779428903 @default.
- W2273948891 hasConceptScore W2273948891C2779438470 @default.
- W2273948891 hasConceptScore W2273948891C2780007613 @default.
- W2273948891 hasConceptScore W2273948891C2780426850 @default.
- W2273948891 hasConceptScore W2273948891C2780580887 @default.
- W2273948891 hasConceptScore W2273948891C502942594 @default.
- W2273948891 hasConceptScore W2273948891C71924100 @default.
- W2273948891 hasConceptScore W2273948891C88045685 @default.
- W2273948891 hasIssue "16_suppl" @default.
- W2273948891 hasLocation W22739488911 @default.
- W2273948891 hasOpenAccess W2273948891 @default.
- W2273948891 hasPrimaryLocation W22739488911 @default.
- W2273948891 hasRelatedWork W1986784478 @default.
- W2273948891 hasRelatedWork W1996682859 @default.
- W2273948891 hasRelatedWork W2051685739 @default.
- W2273948891 hasRelatedWork W2062698051 @default.
- W2273948891 hasRelatedWork W2067349765 @default.
- W2273948891 hasRelatedWork W2096460461 @default.
- W2273948891 hasRelatedWork W2117150911 @default.
- W2273948891 hasRelatedWork W2154264025 @default.
- W2273948891 hasRelatedWork W3161488459 @default.
- W2273948891 hasRelatedWork W4254049098 @default.
- W2273948891 hasVolume "23" @default.
- W2273948891 isParatext "false" @default.
- W2273948891 isRetracted "false" @default.
- W2273948891 magId "2273948891" @default.
- W2273948891 workType "article" @default.